The combination of screening IL-2 mutants for superior interaction with the β- and γ-subunit of the IL-2 receptor and developments of chimeric proteins by fusion of the cytokine to proteins like albumin or IgG for half-life extension, already led to promising results in cancer studies [104, 123, 124]. This evidence concerns the gene IL2 and cancer.